Evidence map›Paper›PMID 42852007›Full record

ArticleThe Yale journal of biology and medicine2026

AAVcc47-

Marán Y Hernández Rodríguez, Debolina D Biswas, Sara El Abiad, David Fiflis, Eliana Balle, Gabriela Mautner, Yazan Alibrahim, Amr Elmahalawy, Andrea Dela Pena, Aravind Asokan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Yale journal of biology and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marán Y Hernández RodríguezPediatrics Duke University.
Debolina D BiswasPediatrics Duke University.ORCID https://orcid.org/0000-0003-1305-0149
Sara El AbiadPediatrics Duke University.
David FiflisSurgery Duke University.
Eliana BallePediatrics Duke University.
Gabriela MautnerPediatrics Duke University.
Yazan AlibrahimPediatrics Duke University.
Amr ElmahalawyPediatrics Duke University.
Andrea Dela PenaPediatrics Duke University.
Aravind AsokanSurgery Duke University.
Mai K ElMallahPediatrics Duke University.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is a progressive X-linked neuromuscular disorder caused by deficiency of dystrophin - a protein essential for muscle integrity. Loss of dystrophin results in global muscle weakness, including in the muscles of respiration. As a result, respiratory failure is a leading cause of morbidity and mortality in patients with DMD. Gene therapy using adeno-associated virus (AAV) is ideal for monogenetic diseases. However, the dystrophin gene is too large to be packaged into AAV; therefore, microdystrophin (

Indexed as

DependovirusDystrophinGenetic TherapyMuscular Dystrophy, DuchenneAnimalsDiaphragmDisease Models, AnimalGene Therapy AgentsGenetic VectorsMaleMiceMice, Inbred C57BLMice, Inbred mdxDystrophinAAV gene therapybreathingDuchenne Muscular DystrophyFlexiVentforced oscillometryrespiratory dysfunctionWhole body plethysmography

Identifiers

PMID42852007
PMCPMC13648078

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.